SEC Filing Summary: Form 13F-HR
Business Context and Reporting Period
This filing is a Form 13F-HR (Holdings Report) submitted by Gilead Sciences, Inc., acting as an Institutional Investment Manager. The report covers the quarter ended March 31, 2026, and was signed on May 8, 2026, by Andrew D. Dickinson, Executive Vice President and Chief Financial Officer. The report includes holdings for Gilead Sciences, Inc. and one other included manager, Gilead Therapeutics A1 Unlimited Co.
Key Financial Metrics
As a Form 13F filing, this document reports equity holdings rather than the operating financial performance of Gilead Sciences, Inc. itself. Consequently, revenue, profit, cash flow, margins, debt, and liquidity metrics for the company are not disclosed in this text.
- Total Value of Reported Holdings: $2,117,784,504
- Number of Holdings Reported: 6
- Number of Other Included Managers: 1
Material Changes
The filing text does not provide comparative data against the prior period (December 31, 2025) or detail specific material changes in holdings, as the input contains only the cover page and summary totals.
Guidance, Outlook, and Risks
This filing type does not contain management commentary, forward-looking guidance, risk factors, or contingencies regarding the company's business operations. It strictly discloses the portfolio of securities held by the reporting manager.
Key Facts for Investor Verification
- Verify the specific 6 equity positions held by Gilead Sciences, Inc. as an investment manager, as the detailed list is not included in the provided text.
- Confirm the total portfolio value of approximately $2.12 billion represents the aggregate value of the reported securities.
- Note that this filing reflects Gilead's role as an investment manager, not its own corporate financial health or operational results.
- Check the associated filing for "Gilead Therapeutics A1 Unlimited Co" (File No. 028-25083) for additional context on the included manager.